Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

Novo Nordisk is pursuing a preliminary injunction to stop Eli Lilly from running specific advertisements for its weight-loss medications. The pharmaceutical company is seeking a court order to halt these drug ads, initiating a legal battle between the two industry giants over marketing practices in the obesity treatment sector. This legal action aims to restrict the promotional activities of Eli Lilly regarding its weight-loss products through a formal judicial intervention by the court system.